MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product

EQS-News: MorphoSys AG


/ Key word: Forecast





MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces...

Related Keywords

United States , Boston , Massachusetts , Germany , Canada , Planegg , Bayern , Julia Neugebauer , Thomas Biegi , Jean Paul Kress , Eamonn Nolan , Drug Administration , Xencor Inc , European Medicines Agency , Corporate Affairs , Constellation Pharmaceuticals Inc , Corporate Communications Investor Relations , Nasdaq , Linkedin , Exchange Commission , Twitter , Lymphoma Society , Sys Reports Preliminary , Product Sales , Gross Margin , Reduces Financial , Chief Executive Officer , Morphosy Phase , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Prescribing Information , Morphosy Annual Report , Vice President , Global Investor , Corporate Communications , Markets ,